December 8, 2021
Awakn Life Sciences recently signed a memorandum of understanding with Devon Partnership NHS Trust and the University of Exeter, to
December 1, 2021
In 2021, psychedelic medicines moved from the frontiers of scientific research to the front pages of newspapers worldwide. This was
November 23, 2021
To strengthen the adoption of psychedelic-assisted therapies, drug developers are striving to minimise their cost – with shorter lasting tryptamines.
November 17, 2021
Member of Parliament Crispin Blunt has championed the campaign to reschedule psilocybin for scientific and research purposes in the UK.
November 10, 2021
This week COMPASS Pathways provided an eagerly anticipated update from its Phase IIb clinical trial. The largest ever study with
November 3, 2021
Cybin became the first psychedelic healthcare company to list on the New York Stock Exchange, with its psilocybin formulation to
October 27, 2021
At Prime Minister’s Questions on 19 October, Boris Johnson responded to Tory MP Crispin Blunt’s call to reschedule psilocybin. Johnson
October 19, 2021
Numinus has completed C$40.3 million in bought deal financing and recently reported quarterly revenues over C$500,000. In September the company
October 12, 2021
Small Pharma recently completed a Phase I trial to treat Major Depressive Disorder (MDD), with proprietary DMT formulation SPL026. The
October 6, 2021
On Monday, 4 October, PSYCH released the third edition of The Psychedelics as Medicine Report. The 200+ page report examines
September 29, 2021
In the research briefing: How ayahuasca ceremony leaders regard preparation and integration Psychedelics for treating neurodegenerative disorders such as Alzheimer’s
September 22, 2021
Professor David Nutt is the Chief Research Officer at Awakn Life Sciences. A former Director of the Neuropsychopharmacology Unit at Imperial
